A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Tarannum Jaleel

Who can participate?    

  • Must be at least 18 years old and no older than 65
  • Have had a diagnosis of Hidradenitis Suppurativa for at least 6 months

How long is the study?    

  • Up to 51 weeks

What does it entail?    

  • Intravenous (IV) infusions (either LY3041658 or placebo) every two weeks for the first 16 weeks
  • IV infusions of LY3041658 (600 mg) every 2 weeks for 20 weeks

Recruitment for this trial has ended. The trial is currently ongoing.